GlassScriptPhysician profile
Leslie A Murphy
NPI 1881677813
$7,815.86
in general payments reported to CMS, 2019-2025
46 companies · $994 in 2025
The $994 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,090 · 2020: $989 · 2021: $1,247 · 2022: $1,385 · 2023: $981 · 2024: $1,129 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.92 | 2019-2025 | |
| Novo Nordisk INC | $1,060.53 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Glaxosmithkline, LLC. | $685.51 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $637.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $472.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $444.59 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.48 | 2019-2025 | Ofev |
| Astellas Pharma US INC | $284.16 | 2020-2025 | Veozah, Xtandi, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $221.73 | 2019-2025 | |
| Amgen INC. | $216.10 | 2019-2023 | Evenity, Prolia, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $199.80 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $189.49 | 2019-2025 | Gardasil 9, Capvaxive, Vaxelis |
| Exact Sciences Corporation | $172.69 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $119.53 | 2023-2025 | Injectafer |
| Janssen Pharmaceuticals, INC | $107.83 | 2019-2023 | Xarelto |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.